Objectives: To investigate the presence and the genetic environment of the multiresistance gene cfr in Jeotgalicoccus pinnipedialis and Macrococcus caseolyticus from pigs.
Introduction
The multidrug resistance gene cfr was originally identified as a chloramphenicol-florfenicol resistance determinant on the multiresistance plasmid pSCFS1 from bovine Staphylococcus sciuri in 2000. 1 Further studies indicated that Cfr methyltransferase catalyses methylation of A2503 in the 23S rRNA gene of the large ribosomal subunit. This configuration confers resistance to chemically unrelated classes of antimicrobial agents, including phenicols, oxazolidinones, lincosamides, pleuromutilins and streptogramin A, and decreased susceptibility to the 16-membered macrolides spiramycin and josamycin. 2, 3 The veterinary use of phenicols (florfenicol), lincosamides (clindamycin, pirlimycin and lincomycin) and pleuromutilins (tiamulin and valnemulin) for treatment or prevention of bacterial diseases may provide the selective pressure for the spread of cfr-mediated multiresistance. Based on the frequency of detection, coagulasenegative staphylococci, which commonly colonize livestock, may constitute the main reservoir of cfr in veterinary medicine. 4, 5 However, it should be noted that cfr-positive Staphylococcus aureus strains have also been identified in both human and veterinary medicine. 6 Recent studies from China showed that the presence of the cfr gene is not restricted to staphylococci as it has been found in porcine Bacillus spp., 7 bovine Enterococcus faecalis, 8 and even in Proteus vulgaris 9 and Escherichia coli 10 of porcine origin.
In this study, we report for the first time the presence of plasmids harbouring the cfr gene in species from two genera of Gram-positive bacteria, Macrococcus caseolyticus and Jeotgalicoccus pinnipedialis, both of porcine origin.
Materials and methods
Sample collection, detection of florfenicol resistance genes and species assignment
In 2010, nasal swabs were collected from 557 individual animals during a survey for the presence of cfr in bacteria from pigs. Samples were collected from three pig farms in Shandong province, China. Samples were streaked on brain heart infusion (BHI) agar plates supplemented with 10 mg/L florfenicol. The resulting colonies were screened using PCR for the currently known florfenicol resistance genes, cfr, fexA, fexB and floR, using previously described primers. 7, 9, 11 Species assignment of the cfr-carrying strains was performed by Gram's staining, colony morphology analysis, 16S rDNA sequencing and the use of a commercially available biochemical test system (ID32 STAPH; bioMérieux, Craponne, France).
Susceptibility testing, transformation experiments and molecular analyses
MICs of the antimicrobial agents listed in Table 1 were determined by broth microdilution according to the recommendations for staphylococci given in document M100-S21 of the CLSI. S. aureus ATCC 29213 was used as a quality control strain.
Plasmid DNA was introduced into recipient strain S. aureus RN4220 by electrotransformation. 7 Transformants were selected on BHI agar plates supplemented with 10 mg/L florfenicol, and presence of the cfr gene in transformants was further confirmed by PCR. Plasmids were extracted from the transformants, and their sizes were estimated by electrophoresis and by comparison with plasmid standards purified from E. coli V517. These transformants were subsequently assayed for MICs of the antimicrobial agents and combinations of antimicrobial agents listed in Table 1 .
Genomic DNA was isolated from bacteria using a Wizard Genomic DNA Purification Kit (Promega, Beijing, China). Plasmids were extracted using a QIAGEN Midi plasmid extraction kit (Qiagen, Hilden, Germany). Southern blotting was used to determine the location of each cfr gene. 9 The flanking regions of each cfr gene were sequenced by primer walking and a modified random primer walking sequencing strategy, as previously described. 9 A 1466 bp amplicon, corresponding to the 16S rDNA gene, was obtained for each species using universal bacteria-specific primers 27F (5 ′ -AGAGTTTGATCCTGGCTCAG-3 ′ ) and 1492R (5 ′ -GGCTACCTTGTTACGACTT-3 ′ ). 9 Amplicons were sequenced by the Beijing Genomic Institution (BGI, Beijing, China). Further resistance genes, such as erm(C), erm(B) and aacA-aphD, present on previously described cfr-carrying plasmids, were detected by PCR. 5, 7 Results and discussion Analysis of 75 Gram-positive non-staphylococcal and nonenterococcal isolates collected from 391 bacterial isolates with florfenicol MICs ≥ 16 mg/L from the 557 samples tested for the presence of florfenicol resistance genes revealed that three isolates, designated K3 (from farm 1), 102 (farm 1) and 207 (farm 2), carried the cfr gene. Sequence analysis confirmed that the nucleotide sequence of the cfr gene in each of these three isolates showed 100% identity to the cfr gene found on plasmid pSCFS1 from S. sciuri (accession number NC_005076). 1 Gram's staining, colony morphology, ID32 STAPH tests and 16S rDNA sequencing identified isolates K3 and 207 as M. caseolyticus, while isolate 102 was Gram-positive but could not be identified by the ID32 STAPH system. However, 16S rDNA sequencing of isolate 102 revealed .99% nucleotide sequence identity to the 16S rDNA sequence of J. pinnipedialis. To the best of our knowledge, this is the first report of the multiresistance gene cfr in M. caseolyticus and J. pinnipedialis. M. caseolyticus, a commensal bacterium of livestock, is typically isolated from animal skin and food products, such as milk and meat.
12 J. pinnipedialis was originally isolated from a Southern elephant seal (Mirounga leonina). 13 To date, little is known about this genus; however, some investigations have indicated that bacteria belonging to the genus Jeotgalicoccus are widely distributed in the environment. 13 The existence of the cfr gene in these ubiquitous free-living bacteria implies a wide distribution of this multiresistance gene, both in veterinary settings and the surrounding environment.
All three isolates showed high MICs of chloramphenicol, florfenicol, clindamycin, erythromycin, tiamulin, valnemulin, kanamycin and gentamicin, but exhibited low MICs of amoxicillin/ clavulanic acid, ceftazidime, ceftiofur, ciprofloxacin, trimethoprim and sulfamethoxazole/trimethoprim (Table 1) . Plasmid analysis indicated that isolates K3, 207 and 102 contained plasmids of different sizes (data not shown). Electrotransformation identified that a 7 kb plasmid from M. caseolyticus K3 and a 53 kb plasmid from both M. caseolyticus 207 and J. pinnipedialis 102 were associated with phenicol resistance. Interestingly, the 7 kb plasmid isolated from K3 presented an EcoRI restriction pattern that was indistinguishable from that of plasmid pSS-03, originally identified in coagulase-negative staphylococci. 5 Sequence analysis revealed that the 7057 bp plasmid is indeed pSS-03. Interestingly, the pSS-03-carrying M. caseolyticus K3 was isolated from pig farm 1, where plasmid pSS-03 had also been detected in two S. sciuri, two Staphylococcus cohnii and one Staphylococcus saprophyticus. 5 This observation suggested an intergenus transfer of this small plasmid between staphylococci and M. caseolyticus. In addition, the 53 kb plasmids from transformants of M. caseolyticus 207 and J. pinnipedialis 102, designated pJP1, showed indistinguishable HindIII and XbaI restriction patterns, and the corresponding S. aureus RN4220 transformants exhibited the same MICs of all tested antimicrobial agents (Table 1) . Southern blot analysis confirmed the presence of cfr on both 53 kb plasmids in the original strains and on that of the transformants (data not shown). The existence of plasmid pJP1 in strains M. caseolyticus 207 and J. pinnipedialis 102 suggests that this cfr-carrying plasmid can replicate in, and be disseminated between, different genera of Gram-positive bacteria. Susceptibility testing of transformants RN4220 +pJP1 and RN4220 + pSS-03 showed that both plasmids conferred increased MICs of chloramphenicol, florfenicol, clindamycin, tiamulin, valnemulin, linezolid and erythromycin (Table 1 ). In addition, RN4220 +pJP1 showed elevated MICs of aminoglycosides, including gentamicin (64 mg/L), kanamycin (64 mg/L) and neomycin (4 mg/L).
The sequenced 8896 bp part of plasmid pJP1 (accession number JQ320084) revealed a segment of 4698 bp that cfr in M. caseolyticus and J. pinnipedialis comprised the insertion sequence IS21-558 and the cfr gene and showed 99.7% (4685/4698 bp) identity to the corresponding segment of the S. aureus plasmid pSCFS3 (accession number AM086211) (Figure 1) . 4 This IS21-558 element has been reported to play an important role in the mobility of cfr.
14 The 1612 bp upstream region of IS21-558, which contained the kanamycin/neomycin resistance gene aadD and the bleomycin resistance gene ble, showed 100% identity to the S. aureus plasmid pGO1 (accession number FM207042).
14 The tnp gene downstream of the cfr gene in pJP1 presented 76% amino acid identity to a putative transposase in Bacillus cereus AH820 plasmid pAH820_272 (accession number AM159501). PCR screening for macrolide and gentamicin resistance genes in S. aureus RN4220 +pJP1 revealed the presence of the genes erm(C) and aacA-aphD. The coexistence of the cfr gene and the aminoglycoside resistance genes aadD and aacA-aphD in pJP1 as well as the macrolide -lincosamide -streptogramin B resistance gene erm(C) in pSS-03 and pJP1 will allow persistence and co-selection of the cfr gene under selective pressure of aminoglycosides or macrolides.
In summary, this study extends the known host range of the staphylococcal multiresistance gene cfr. Although there are no reports of M. caseolyticus or J. pinnipedialis being isolated from humans, the presence of cfr-carrying plasmids in these genera may allow horizontal transfer to other commensal or pathogenic bacteria, such as staphylococci or enterococci, in the agricultural environment. It may also be possible for these plasmids to find their way through the food chain to commensal or pathogenic bacteria of humans, which then may result in a non-negligible threat to public health. Wang et al.
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